Certain Restricted Stock Units of Calyxt, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2018.
January 16, 2018
Share
Certain Restricted Stock Units of Calyxt, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2018. These Restricted Stock Units will be under lockup for 181 days starting from 19-JUL-2017 to 16-JAN-2018.
Details:
The directors, executive officers, Cellectis S.A., and other security holders have entered into a lock up agreement pursuant to which, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, for a period of 180 days from the date of the prospectus, without the prior written consent of the representatives of the underwriters.
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.